Integra LifeSciences (NASDAQ:IART) Posts Earnings Results, Beats Expectations By $0.02 EPS

Integra LifeSciences (NASDAQ:IART) issued its quarterly earnings results on Monday. The life sciences company reported $0.41 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.02, Briefing.com reports. Integra LifeSciences had a positive return on equity of 12.25% and a negative net margin of 0.42%. The business had revenue of $380.80 million during the quarter, compared to the consensus estimate of $375.81 million. During the same period in the previous year, the business earned $0.76 EPS. The business’s quarterly revenue was down .4% on a year-over-year basis.

Integra LifeSciences Stock Down 1.9 %

NASDAQ:IART traded down $0.50 during trading hours on Thursday, hitting $26.20. 87,751 shares of the company’s stock traded hands, compared to its average volume of 1,100,250. The firm has a market cap of $2.03 billion, a P/E ratio of -289.67, a P/E/G ratio of 0.82 and a beta of 1.08. Integra LifeSciences has a twelve month low of $16.81 and a twelve month high of $45.42. The company has a debt-to-equity ratio of 1.17, a quick ratio of 2.10 and a current ratio of 3.39. The stock’s fifty day moving average price is $18.90 and its two-hundred day moving average price is $24.40.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on IART. JMP Securities reduced their price objective on Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating for the company in a research report on Tuesday, July 30th. Citigroup boosted their price objective on Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a research report on Tuesday. BTIG Research upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating in a research report on Monday, October 7th. Truist Financial reduced their price objective on Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating for the company in a research report on Monday, October 14th. Finally, Bank of America reduced their price objective on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a research report on Monday, October 7th. Three analysts have rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the company. According to MarketBeat, Integra LifeSciences presently has an average rating of “Hold” and a consensus target price of $27.25.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.